Investor Alert

Oct. 29, 2021, 11:02 a.m. EDT

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Rafael Holdings, Inc. (RFL) Investigation

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Rafael Holdings Inc. (RFL)

or Cancel Already have a watchlist? Log In

October 29, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / October 29, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rafael Holdings, Inc. ("Rafael" or the "Company") /zigman2/quotes/206275218/composite RFL -3.87% . Investors who purchased Rafael shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rfl .

Image: https://www.accesswire.com/users/newswire/images/670308/BRONSTEIN200.jpg

The investigation concerns whether Rafael and certain of its officers and/or directors have violated federal securities laws.

On October 28, 2021, Rafael issued a press release "announc[ing] that the AVENGER 500 Phase 3 clinical trial for CPI-613® (devimistat), Rafael Pharmaceuticals' lead product candidate, did not meet its primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the pancreas." On this news, Rafael's stock price fell sharply during intraday trading on October 28, 2021.

If you are aware of any facts relating to this investigation, or purchased Rafael shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/rfl . You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

View source version on accesswire.com:



Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2021 ACCESSWIRE

$ 1.74
-0.07 -3.87%
Volume: 135,533
May 20, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$36.20 million
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.